Glenmark becomes the first company to launch Indacaterol + Mometasone FDC for asthma in India
Glenmark is the first company in India to market the innovative FDC of Indacaterol
Glenmark is the first company in India to market the innovative FDC of Indacaterol
The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”
Subscribe To Our Newsletter & Stay Updated